entertainment -WSS

entertainment

author：focus 2025-08-23 08:57:34 - browse：5134

STAT's Megan Molteni speaks with Feng Zhang in New York on March 21, 2024 — Scientist Feng Zhang, right, is interviewed by reporter Megan Molteni at STAT's Breakthrough Summit East. STAT

When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter. It locked up some of the crucial IP, and had behind it the pioneering scientist Feng Zhang of the Broad Institute as one of its founders.

But now, a decade later, Editas is seen as lagging behind its peers. CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, won the race to get the first CRISPR-based medicine across the finish line. Intellia Therapeutics was the first to show that CRISPR editing could be performed inside the body. Editas, meanwhile, has seen a revolving door among its executives.

So what happened?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Involuntary treatment for addiction doesn't work

focus

WSS

The new HIV moral panic

Families look for replacement for GSK asthma drug Flovent

First over

Care demand spikes challenge UnitedHealth’s provider arm

Lack of health data on LGBTQ+ people has serious consequences

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

focus

entertainment

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

Why police arrested suspected Gilgo Beach killer away from his house

Duchenne breakthrough therapy leaves behind pioneering families

Federal judge rules Oregon’s tough new gun law is constitutional

Medicare proposal to cover medical devices draws a mixed reaction

Involuntary treatment for addiction doesn't work

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why police arrested suspected Gilgo Beach killer away from his house

ChatGPT in medicine: STAT answers readers' burning questions

J&J expands global access to TB drug amid advocacy campaign

leisure time

Europe sees delivery challenges ahead on Alzheimer's therapies

Pregnant women don't need prenatal multivitamins, study concludes

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Woman gored by Bison at Yellowstone

He's 19 months old and has one of the world’s rarest diseases

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

focus

focus

explore

focus